无法在这个位置找到： ”baidu_js_push.htm”
今日热点推荐：
爱地那非是什么？悦康“爱力士”
加入收藏 | 设为首页 | 热门搜索 |
网站地图
ASH | CAR-T疗法领域的进步成为关注的亮点(4)
2020-05-27 未知 admin
[2] Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma. Retrieved December 8, 2019, from https://www.businesswire.com/news/home/20191207005035/en.
[3] Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study. Retrieved December 8, 2019, form https://www.businesswire.com/news/home/20191207005032/en.
[4] Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma. Retrieved December 8, 2019, from https://www.businesswire.com/news/home/20191206005463/en/Bristol-Myers-Squibb-bluebird-bio-Announce-Positive-Top-line
[5] New Approaches Aim to Enhance CAR T-Cell Therapy. Retrieved December 8, 2019, from https://www.hematology.org/Newsroom/Press-Releases/2019/10096.aspx
原标题：ASH | 缓解率100%！杨森/南京传奇CAR-T疗法结果惊艳，BMS两款CAR-T疗法将递交监管申请
*声明：本文由入驻新浪医药新闻作者撰写，观点仅代表作者本人，不代表新浪医药新闻立场。▽关注【药明康德】微信公众号
鐑瘝锛�
